PARP抑制剂疗效依赖CD8+ T细胞募集:BRCA缺陷三阴性乳腺癌模型中肿瘤内STING通路激活的作用
本研究探讨PARP抑制剂奥拉帕利在BRCA1缺陷三阴性乳腺癌肿瘤微环境中的作用机制。奥拉帕利诱导CD8+ T细胞浸润和活化,CD8+ T细胞耗竭严重削弱抗肿瘤疗效;该过程由肿瘤细胞cGAS/STING通路激活介导,并在HR缺陷细胞和体内模型中更明显。
要点
- 奥拉帕利在体内诱导CD8+ T细胞浸润和活化,CD8+ T细胞耗竭严重削弱抗肿瘤疗效。
- 奥拉帕利诱导的T细胞募集由肿瘤细胞cGAS/STING通路激活介导,并旁分泌激活树突状细胞。
- CRISPR敲除肿瘤细胞STING足以消除奥拉帕利诱导的体内T细胞浸润。
核心结论
- PARP抑制剂诱导的CD8+ T细胞浸润和活化是其抗肿瘤疗效的重要机制,该过程依赖肿瘤细胞STING/TBK1/IRF3通路激活。
研究设计与样本
- 研究采用BRCA1缺陷三阴性乳腺癌(TNBC)的细胞和体内模型,使用PARP抑制剂奥拉帕利处理,并通过CD8+ T细胞耗竭和CRISPR介导的STING敲除进行机制验证。
主要发现
- 奥拉帕利在体内诱导CD8+ T细胞浸润和活化,CD8+ T细胞耗竭严重削弱抗肿瘤疗效。
- 奥拉帕利诱导的T细胞募集由肿瘤细胞cGAS/STING通路激活介导,并旁分泌激活树突状细胞。
- 奥拉帕利诱导的T细胞募集在HR缺陷TNBC细胞和体内模型中比HR proficient更明显。
- CRISPR敲除肿瘤细胞STING阻止促炎信号并足以消除奥拉帕利诱导的体内T细胞浸润。
临床怎么用
- 作者认为这些发现阐明了PARP抑制剂的额外作用机制,并为PARP抑制联合免疫治疗用于TNBC提供了依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC). We demonstrate that the PARP inhibitor olaparib induces CD8+ T-cell infiltration and activation in vivo, and that CD8+ T-cell depletion severely compromises antitumor efficacy. Olaparib-induced T-cell recruitment is mediated through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and is more pronounced in HR-deficient compared with HR-proficient TNBC cells and in vivo models. CRISPR-mediated knockout of STING in cancer cells prevents proinflammatory signaling and is sufficient to abolish olaparib-induced T-cell infiltration in vivo. These findings elucidate an additional mechanism of action of PARP inhibitors and provide a rationale for combining PARP inhibition with immunotherapies for the treatment of TNBC. SIGNIFICANCE: This work demonstrates cross-talk between PARP inhibition and the tumor microenvironment related to STING/TBK1/IRF3 pathway activation in cancer cells that governs CD8+ T-cell recruitment and antitumor efficacy. The data provide insight into the mechanism of action of PARP inhibitors in BRCA-associated breast cancer.This article is highlighted in the In This Issue feature, p. 681.
引用
- Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov. 2019. PMID: 31015319. doi:10.1158/2159-8290.CD-18-1218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。